Option chain shows key data for Nexus Energy Services's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Nexus Energy Services.

Nexus Energy Services (OTC:IBGR) Stock, Option Chain

Nexus Energy Services Inc is a performance athletic brand offering superior quality apparel, footwear, and gear products. The company's products include T-Shirts & Bras, Shorts, Pants & Leggings Sweatshirts & Hoodies Soccer Jerseys and accessories for women, T-Shirts & Singlets, Pants & Shorts, Jackets & Hoodies, Jerseys and Accessories for men as well.

dryworld

News

NEXUS ENERGY SERVICES INC by Nexus Energy Services, Inc.

IBGR

DRYWORLD Brands Inc. (OTC: IBGR) saw a 1,700% sales increase in Q1 2024. Plans to expand globally and up-list to OTCQB in 2024. Co-CEO confident in brand&#39;s growth and shareholder value.

DRYWORLD Brands Clocks 1,700% Sales Growth In Q1, e-Commerce Revenue Soars

Cannabis

Penny Stocks

Markets

BLMS

Bloomios To Manufacture DRYWORLD&#39;s New Athletic Performance CBD Product Line

Nexus Energy Services Inc

In the preceding three months, 4 analysts have released ratings for Immunocore Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMCR#NASDAQ">IMCR</a>), presenting a wide array of perspectives from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $69.25, a high estimate of $100.00, and a low estimate of $35.00. Highlighting a 12.34% decrease, the current average has fallen from the previous average price target of $79.00. 
<img src="https://www.benzinga.com/files/images/story/2025/1740657629_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Immunocore Hldgs. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gil Blum</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$71.00</td>
<td>$71.00</td>
</tr>
<tr>
<td>Patrick Trucchio</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$100.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Gil Blum</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$71.00</td>
<td>$71.00</td>
</tr>
<tr>
<td>Andrew Galler</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$35.00</td>
<td>$74.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Immunocore Hldgs. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Immunocore Hldgs compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Immunocore Hldgs's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
For valuable insights into Immunocore Hldgs's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/IMCR/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Immunocore Hldgs analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Delving into Immunocore Hldgs's Background</h2>
Immunocore Holdings PLC is a late-stage biotechnology company engaged in the development of a novel class of TCR bispecific immunotherapies for the treatment of cancer, infectious and autoimmune diseases. Its geographical segments are the United Kingdom and the United States, of which the majority of its revenue comes from the United States.
<h3>Immunocore Hldgs's Financial Performance</h3>
Market Capitalization Analysis: Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.
Revenue Growth: Immunocore Hldgs's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of 23.74%. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Immunocore Hldgs's net margin excels beyond industry benchmarks, reaching 10.89%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 2.37%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Immunocore Hldgs's ROA excels beyond industry benchmarks, reaching 0.83%. This signifies efficient management of assets and strong financial health.
Debt Management: Immunocore Hldgs's debt-to-equity ratio is notably higher than the industry average. With a ratio of 1.27, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

IMCR

What Analysts Are Saying About Immunocore Hldgs Stock

8 analysts have expressed a variety of opinions on Freeport-McMoRan (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FCX#NYSE">FCX</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $46.62, a high estimate of $50.00, and a low estimate of $40.00. This current average represents a 8.59% decrease from the previous average price target of $51.00. 
<img src="https://www.benzinga.com/files/images/story/2025/1740657620_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Freeport-McMoRan. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chris LaFemina</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$48.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Orest Wowkodaw</td>
<td>Scotiabank</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$45.00</td>
<td>$48.00</td>
</tr>
<tr>
<td>Katja Jancic</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$50.00</td>
<td>$54.00</td>
</tr>
<tr>
<td>Chris LaFemina</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Hold</td>
<td>$40.00</td>
<td>$48.00</td>
</tr>
<tr>
<td>Bill Peterson</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$48.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Bob Brackett</td>
<td>Bernstein</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$46.00</td>
<td>$51.00</td>
</tr>
<tr>
<td>Orest Wowkodaw</td>
<td>Scotiabank</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$48.00</td>
<td>$52.00</td>
</tr>
<tr>
<td>Chris LaFemina</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Buy</td>
<td>$48.00</td>
<td>$60.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Freeport-McMoRan. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Freeport-McMoRan compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Freeport-McMoRan's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Freeport-McMoRan's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/FCX/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Freeport-McMoRan analyst ratings.</a>
<h2>Unveiling the Story Behind Freeport-McMoRan</h2>
Freeport-McMoRan owns stakes in 10 copper mines, led by its 49% ownership of the Grasberg copper and gold operations in Indonesia, 55% of the Cerro Verde mine in Peru, and 72% of Morenci in Arizona. It sold around 1.2 million metric tons of copper (its share) in 2024, making it the one of the world's largest copper miners by volume. It also sold about 900,000 ounces of gold, mostly from Grasberg, and 70 million pounds of molybdenum. It had about 25 years of copper reserves at end December 2024. we expect it to sell similar amounts of copper midcycle in 2029, though we expect gold volumes to decline to about 700,000 ounces then due to falling production at Grasberg.
<h3>Freeport-McMoRan: Delving into Financials</h3>
Market Capitalization: Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.
Negative Revenue Trend: Examining Freeport-McMoRan's financials over 3 months reveals challenges. As of 31 December, 2024, the company experienced a decline of approximately -3.13% in revenue growth, reflecting a decrease in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Materials sector.
Net Margin: Freeport-McMoRan's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of 4.79%, the company may face hurdles in effective cost management.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of 1.56%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of 0.5%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: Freeport-McMoRan's debt-to-equity ratio stands notably higher than the industry average, reaching 0.55. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>Analyst Ratings: Simplified</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What Analysts Are Saying About Freeport-McMoRan Stock

Clear Secure (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YOU#NYSE">YOU</a>) has been analyzed by 4 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $43.5, along with a high estimate of $45.00 and a low estimate of $42.00. The current average, unchanged from the previous average price target, holds steady. 
<img src="https://www.benzinga.com/files/images/story/2025/1740657612_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
The standing of Clear Secure among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joshua Reilly</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$45.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>Dana Telsey</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$42.00</td>
<td>$42.00</td>
</tr>
<tr>
<td>Dana Telsey</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$42.00</td>
<td>$42.00</td>
</tr>
<tr>
<td>Joshua Reilly</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$45.00</td>
<td>$45.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Clear Secure. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Clear Secure compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Clear Secure's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of Clear Secure's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/YOU/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Clear Secure analyst ratings.</a>
<h2>Discovering Clear Secure: A Closer Look</h2>
Clear Secure Inc is an identity company making experiences safer and easier digitally and physically. It is involved in the creation of a frictionless travel experience while enhancing security. Its secure identity platform uses biometrics to automate the identity verification process through lanes in airports which helps to make the travel experience safe and easy.
<h3>Unraveling the Financial Story of Clear Secure</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Growth: Over the 3 months period, Clear Secure showcased positive performance, achieving a revenue growth rate of 23.72% as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Information Technology sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 11.83%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Clear Secure's ROE excels beyond industry benchmarks, reaching 16.61%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Clear Secure's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 2.55% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Clear Secure's debt-to-equity ratio stands notably higher than the industry average, reaching 0.95. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>How Are Analyst Ratings Determined?</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Breaking Down Clear Secure: 4 Analysts Share Their Views

HC Wainwright &amp; Co. analyst Raghuram Selvaraju reiterates MoonLake (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLTX#NASDAQ">MLTX</a>) with a Buy and maintains $100 price target.

Price Target

Reiteration

MLTX

HC Wainwright & Co. Reiterates Buy on MoonLake, Maintains $100 Price Target

Starwood Prop Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STWD#NYSE">STWD</a>) reported quarterly earnings of $0.48 per share which beat the analyst consensus estimate of $0.47 by 2.13 percent. This is a 17.24 percent decrease over earnings of $0.58 per share from the same period last year. The company reported quarterly sales of $454.39 million which missed the analyst consensus estimate of $478.00 million by 4.94 percent. This is a 13.00 percent decrease over sales of $522.28 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

STWD

Starwood Prop Trust Q4 Adj EPS $0.48 Beats $0.47 Estimate, Sales $454.39M Miss $478.00M Estimate

Buybacks

ADT Announces New $500M Share Buyback Program

WIIM

LFST

LifeStance Health shares are trading higher after the company reported better-than-expected Q4 results and issued FY25 revenue guidance above estimates.

Needham analyst Mayank Tandon maintains ExlService Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXLS#NASDAQ">EXLS</a>) with a Buy and raises the price target from $50 to $60.

EXLS

Needham Maintains Buy on ExlService Hldgs, Raises Price Target to $60

ADT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ADT#NYSE">ADT</a>) reported quarterly earnings of $0.20 per share which beat the analyst consensus estimate of $0.19 by 5.26 percent. This is a 20 percent decrease over earnings of $0.25 per share from the same period last year. The company reported quarterly sales of $1.30 billion which beat the analyst consensus estimate of $1.23 billion by 5.41 percent. This is a 6.38 percent increase over sales of $1.22 billion the same period last year.

ADT Q4 2024 Adj EPS $0.20 Beats $0.19 Estimate, Sales $1.30B Beat $1.23B Estimate

XRAY

Dentsply Sirona shares are trading lower after the company reported worse-than-expected Q4 FY24 financial results and issued guidance.

Guidance

GLNG

Golar LNG Reports Preliminary Q4 Net Income Attributable Of $3M Inclusive Of $29M Of Non-cash Items, And Adjusted EBITDA Of $59M

Barclays analyst Peter Lawson maintains Geron (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GERN#NASDAQ">GERN</a>) with a Overweight and lowers the price target from $9 to $4.

GERN

Barclays Maintains Overweight on Geron, Lowers Price Target to $4

NCLH

Norwegian Cruise Line shares are trading higher after the company reported better-than-expected Q4 EPS and revenue.

Teleflex shares are trading lower after the company issued FY25 EPS guidance below estimates.

WRBY

Warby Parker shares are trading higher after the company reported Q4 sales above estimates.

Barclays analyst Jeffrey Bernstein maintains Bloomin Brands (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLMN#NASDAQ">BLMN</a>) with a Equal-Weight and lowers the price target from $13 to $11.

BLMN

Barclays Maintains Equal-Weight on Bloomin Brands, Lowers Price Target to $11

2025 Full-Year Financial Guidance1
The Company's full-year guidance for 2025 can be found in the table below.
Updates to Subsea guidance, previously issued on October 24, 2024, are as follows:
<ul>
<li>Subsea revenue in a range of $8.4 - 8.8 billion, which increased from the previous guidance range of $8.3 - 8.7 billion.</li>
<li>Subsea adjusted EBITDA margin in a range of 19 - 20%, which increased from the previous guidance range of 18.5 - 20%.</li>
</ul>
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="5" rowspan="1">2025 Guidance (As of February 27, 2025)</td>
</tr>
<tr>
<td colspan="5" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="2" rowspan="1">Subsea</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="2" rowspan="1">Surface Technologies</td>
</tr>
<tr>
<td colspan="2" rowspan="1">Revenue in a range of $8.4 - 8.8 billion</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="2" rowspan="1">Revenue in a range of $1.2 - 1.35 billion</td>
</tr>
<tr>
<td colspan="2" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="2" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="2" rowspan="1">Adjusted EBITDA margin in a range of 19 - 20%</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="2" rowspan="1">Adjusted EBITDA margin in a range of 15 - 16%</td>
</tr>
<tr>
<td colspan="5" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="5" rowspan="1">TechnipFMC</td>
</tr>
<tr>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="5" rowspan="1">Corporate expense, net $115 - 125 million</td>
</tr>
<tr>
<td colspan="5" rowspan="1">(excludes charges and credits)</td>
</tr>
<tr>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="5" rowspan="1">Net interest expense $45 - 55 million</td>
</tr>
<tr>
<td colspan="5" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="5" rowspan="1">Effective tax rate 28 - 32%</td>
</tr>
<tr>
<td colspan="5" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="5" rowspan="1">Capital expenditures approximately $340 million</td>
</tr>
<tr>
<td colspan="5" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="5" rowspan="1">Free cash flow2 $850 million - 1 billion</td>
</tr>
</tbody>
</table>
</figure>

TechnipFMC 2025 Outlook: Raised Subsea Revenue Range To $8.4B - $8.8B From $8.3B - 8.7B And Adj. EBITDA Margin Range To 19% - 20% From 18.5% - 20%.

HC Wainwright &amp; Co. analyst Mitchell Kapoor reiterates Sarepta Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) with a Sell and maintains $75 price target.

SRPT

HC Wainwright & Co. Reiterates Sell on Sarepta Therapeutics, Maintains $75 Price Target

VTRS

Viatris shares are trading lower after the company reported Q4 EPS and sales below estimates.

2025 Financial Guidance
The Company is providing the following financial guidance metrics for fiscal year 2025.
The Company's financial guidance metrics for fiscal year 2025 include the anticipated negative impact from the Indore facility of ~$500 million to total revenues and ~$385 million to adjusted EBITDA. The Company is not providing forward-looking guidance for U.S. GAAP net earnings (loss) or U.S. GAAP diluted earnings (loss)&nbsp;per share (EPS) or a quantitative reconciliation of its 2025 adjusted EBITDA or adjusted EPS guidance to the most directly comparable U.S. GAAP measures, U.S. GAAP net earnings (loss) or U.S. GAAP diluted EPS, respectively, because it is unable to predict with reasonable certainty the ultimate outcome of certain significant items, including integration, acquisition and divestiture-related expenses, restructuring expenses, asset impairments, litigation settlements, and other contingencies, such as changes to contingent consideration, acquired IPR&amp;D and certain other gains or losses, including for the fair value accounting for non-marketable equity investments, as well as related income tax accounting, because certain of these items have not occurred, are out of the Company's control and/or cannot be reasonably predicted without unreasonable effort. These items are uncertain, depend on various factors, and could have a material impact on U.S. GAAP reported results for the guidance period. U.S. GAAP net cash provided by operating activities for 2025 is estimated to be between $2.2 billion and $2.5 billion, with a midpoint of approximately $2.35 billion.
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">(In millions, except Adjusted EPS)</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">Estimated Guidance&nbsp; Range</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">Midpoint</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Total Revenues</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">$13,500 - $14,000</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">$13,750</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted EBITDA (1)(2)</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">$3,900 - $4,200</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">$4,050</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted EPS (1)(2)</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">$2.12 - $2.26</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">$2.19</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Free Cash Flow (1)(2)</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">$1,800 - $2,200</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">$2,000</td>
</tr>
</tbody>
</table>
</figure>

Viatris FY2025 Outlook: Adj EPS $2.12-$2.26 vs $2.60 Estimate; Sees Sales $13.500B-$14.000B vs $14.31B Estimate

Press Releases

DRYWORLD Brands Shares Corporate Update and Highlights Recent Accomplishments

Contracts

DRYWORLD Partners with Legendary Harlem Globetrotter, Curley Boo Johnson, on Skills For Life Basketball Camp

DRYWORLD Marches Into the Madness – Announces Partnership With Purdue Point Guard Braden Smith

Sports

DRYWORLD Partners with Mode Basketball Camp in Ghana

DRYWORLD and Renegade Territory Enter "Era-Defining" Partnership With Grammy-Award Winner, OPLUS

General

PRISM MarketView Features DRYWORLD Brands, A Global High-Performance Athleticwear Brand

DRYWORLD Teams Up with Spartan Race to Revolutionize Performance Apparel in Adventure Racing

Nexus Energy Services

Comments

Nexus Energy Services

Nexus Energy Services (IBGR) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga